Monitoring Myasthenia Gravis with Wearable Sensors
Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis
This study is testing how wearable sensors can help track the health of people with myasthenia gravis to improve their treatment with new medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Heinrich-Heine University, Duesseldorf Academic / other |
| Locations | 1 site (Düsseldorf) |
| Trial ID | NCT06441825 on ClinicalTrials.gov |
What this trial studies
This observational study investigates myasthenia gravis by using wearable devices to continuously monitor patients' health metrics. It integrates digital biomarkers with clinical assessments to better understand disease activity and treatment efficacy. The study focuses on patients treated with newly approved drugs, aiming to enhance individualized treatment approaches. By collecting data on physical activity, cardiovascular health, and sleep quality, researchers hope to establish meaningful correlations that can inform patient care.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a formal diagnosis of generalized myasthenia gravis who can use a smartphone app.
Not a fit: Patients with exclusively ocular symptoms of myasthenia gravis or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and personalized treatment strategies for patients with myasthenia gravis.
How similar studies have performed: While the use of digital biomarkers in chronic disease monitoring is gaining traction, this specific approach in myasthenia gravis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
* Formal diagnosis of generalized Myasthenia Gravis, with at least one of the following criteria: * Response to oral or intravenous administration of an acetylcholinesterase inhibitor * Evidence of pathological decrement/ elevated jitter * Evidence of Myasthenia Gravis-typical antibody (AChR, LRP4, MuSK, Titin) OR other diagnosed Myasthenic Syndrome * Age ≥ 18 * Usage of Smartphone with Android 8.1 (or higher) or IOS12.3 (or higher) * Able to provide informed consent, based on investigator´s judgment Exclusion Criteria: Patients who meet any of the following criteria will be excluded from participation: * Unable or unwilling to give informed consent * Unable or unwilling to use the smartphone app * Any significant comorbidity that might potentially interfere with the ability to successfully participate in the study, based on investigator´s judgment * Patient with exclusively ocular symptoms (ocular myasthenia gravis)
Where this trial is running
Düsseldorf
- Heinrich-Heine University, Duesseldorf — Düsseldorf, Germany (Recruiting)
Study contacts
- Study coordinator: Marc Pawlitzki, PD Dr. med.
- Email: neuro-trials@med.uni-duesseldorf.de
- Phone: +49211 8117887
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.